Allison M. Bock
Rating: 5.0 of 5
( out of 82 reviews )

Allison M. Bock, MD

Languages spoken: English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
2000 Circle of Hope
Salt Lake City , UT 84112
801-585-2626
Get Directions

  • Dr. Allison Bock is an Assistant Professor of Medicine in the Division of Hematology and Hematologic Malignancies. She specializes in treating patients with lymphoma and chronic lymphocytic leukemia. She completed her Internal Medicine residency training at the University of Colorado and fellowship training in Hematology/Oncology at the Mayo Clinic in Rochester, MN. Her research focuses on improving outcomes for patients with lymphomas through the development of clinical trials with novel therapies and investigation of prognostic/predictive biomarkers including biological pathways and mechanisms that lead to therapy resistance. She is the principal investigator on multiple lymphoma clinical trials at Huntsman Cancer Institute, including an investigator-initiated randomized phase 2 study evaluating a bispecific antibody therapy for patients at high risk of relapse post CAR-T. She is also an active participant within the national Southwest Oncology Group. She has medical licensure in the states of UT, WY, MT, and ID in order to provide better access to care for the rural communities HCI serves.

    To schedule an appointment New Patients: 801-585-6906 Returning patients: 801-585-2626 or schedule through MyChart.

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    American Board of Internal Medicine

    Patient Rating

    Rating: 5.0 out of 5
    5.0 /5
    ( out of 82 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    So caring and invested

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Knowledgeable with my situation and relieved my anxiety.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr Bock was incredible. I am glad I found her to help me navigate CLL.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Because of the above: listening carefully, treating me with respect, explaining things, etc., I would recommend Allison Bock to anyone needing her care.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Knowledgeable and caring

    HUNTSMAN CANCER CENTER
    Rating: 4 out of 5

    Dr. Bock was bery helpful to us at a difficult time. She was empathetic with us. She is very knowledgeable and very positive about our treatment.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Listens well to my concerns and provides reasonable solutions and accommodations to support me.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Great Doctor very knowledgeable.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Bock is an exceptional physician who is intelligent, caring, and wise in her recommendations. She listens carefully, and displays compassion. She explains things well and confidently moves in the direction that is best for you as a patient. She is quick in ordering tests to bring about the answers needed for an accurate diagnosis. Most importantly, she has an a way of instilling peace and calm during the unknown. IÕm so grateful I am under her care.

  • Dr. Allison Bock is an Assistant Professor of Medicine in the Division of Hematology and Hematologic Malignancies. She specializes in treating patients with lymphoma and chronic lymphocytic leukemia. She completed her Internal Medicine residency training at the University of Colorado and fellowship training in Hematology/Oncology at the Mayo Clinic in Rochester, MN. Her research focuses on improving outcomes for patients with lymphomas through the development of clinical trials with novel therapies and investigation of prognostic/predictive biomarkers including biological pathways and mechanisms that lead to therapy resistance. She is the principal investigator on multiple lymphoma clinical trials at Huntsman Cancer Institute, including an investigator-initiated randomized phase 2 study evaluating a bispecific antibody therapy for patients at high risk of relapse post CAR-T. She is also an active participant within the national Southwest Oncology Group. She has medical licensure in the states of UT, WY, MT, and ID in order to provide better access to care for the rural communities HCI serves.

    To schedule an appointment New Patients: 801-585-6906 Returning patients: 801-585-2626 or schedule through MyChart.

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Assistant Professor (Clinical)
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    American Board of Internal Medicine

    Education history

    Undergraduate Genetics, Cell Biology and Development; minor in Psychology - University of Minnesota - Twin Cities B.S.
    Professional Medical Medicine; Global Health Pathway - Medical College of Wisconsin M.D.
    Residency Internal Medicine - University of Colorado School of Medicine Resident
    Fellowship Hematology/Oncology - Mayo Clinic Fellow

    Selected Publications

    Journal Article

    1. Simpson HM, Bock A, Cervantes (2022). Policy in clinical practice: Emergency Medicaid and access to allogeneic stem cell transplant for undocumented immigrants. Journal of hospital medicine, 17(1), 50-53. (Read full publication)
    2. Yang F, Long N, Anekpuritanang T, Bottomly D, Savage JC, Lee T, Solis-Ruiz J, Borate U, Wilmot B, Tognon C, Bock AM, Pollyea DA, Radhakrishnan S, Radhakrishnan S, Patel P, Collins RH, Tantravahi S, Deininger MW, Fan G, Druker B, Shinde U, Tyner JW, Press RD, McWeeney S, Agarwal (2022). Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. Blood, 139(8), 1208-1221. (Read full publication)
    3. Canfield GS, Bock A, Mann S, Zimmer S, Somerset H, Franco-Paredes C, Wilson CC, Metter R (2020). A 31-year-old Micronesian Man With Shoulder Fungating Mass. Clinical infectious diseases, 70(5), 973-975. (Read full publication)
    4. Bock AM, Brunmeier A, Wichman CL, Bergl P (2017). Encephalopathy With Psychosis Following Group A Streptococcal Sepsis-An Immune-Mediated Phenomenon?. Psychosomatics, 58(5), 551-555. (Read full publication)
    5. Bock AM, LeVeque M, Camitta B, Talano J (2016). Successful treatment of recurrent CNS disease post-bone marrow transplant in children with familial hemophagocytic lymphohistiocytosis. Pediatric blood & cancer, 63(12), 2154-2158. (Read full publication)
    6. Bock A, Chintamaneni K, Rein L, Frazer T, Kayastha G, MacKinney (2016). Improving pneumococcal vaccination rates of medical inpatients in urban Nepal using quality improvement measures. BMJ quality improvement reports, 5(1), (Read full publication)
    7. Knorr DA, Bock A, Brentjens RJ, Kaufman D (2013). Engineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy. Stem cells and development, 22(13), 1861-9. (Read full publication)
    8. Bock AM, Knorr D, Kaufman D (2013). Development, expansion, and in vivo monitoring of human NK cells from human embryonic stem cells (hESCs) and and induced pluripotent stem cells (iPSCs). Journal of visualized experiments, (74), e50337. (Read full publication)
    9. Bock AM, Cao Q, Ferrieri P, Young JA, Weisdorf D (2013). Bacteremia in blood or marrow transplantation patients: clinical risk factors for infection and emerging antibiotic resistance. Biology of blood and marrow transplantation, 19(1), 102-8. (Read full publication)
    10. Bock AM, Gile JJ, Larson MC, Poonsombudlert K, Tawfiq RK, Maliske S, Maurer MJ, Kabat BF, Paludo J, Inwards DJ, Ayyappan S, Link BK, Ansell SM, Habermann TM, Witzig TE, Nowakowski GS, Cerhan JR, Farooq U, Wang (2023). Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study. Blood cancer journal, 13(1), 169. (Read full publication)
    11. Zayac AS, Landsburg DJ, Hughes ME, Bock AM, Nowakowski GS, Ayers EC, Girton M, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Stepanovic A, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Epperla N, Bond DA, Farooq U, Saad M, Evens AM, Pandya K, Naik SG, Kamdar M, Haverkos B, Karmali R, Oh TS, Vose JM, Nutsch H, Rubinstein PG, Chaudhry A, Olszewski A (2023). High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood advances, 7(21), 6381-6394. (Read full publication)
    12. Hines AS, Koster MJ, Bock AR, Go RS, Warrington KJ, Olteanu H, Lasho TL, Patnaik MM, Reichard K (2023). Targeted testing of bone marrow specimens with cytoplasmic vacuolization to identify previously undiagnosed cases of VEXAS syndrome. Rheumatology (Oxford, England), 62(12), 3947-3951. (Read full publication)
    13. Wenzl K, Stokes ME, Novak JP, Bock AM, Khan S, Hopper MA, Krull JE, Dropik AR, Walker JS, Sarangi V, Mwangi R, Ortiz M, Stong N, Huang CC, Maurer MJ, Rimsza L, Link BK, Slager SL, Asmann Y, Mondello P, Morin R, Ansell SM, Habermann TM, Witzig TE, Feldman AL, King RL, Nowakowski G, Cerhan JR, Gandhi AK, Novak A (2024). Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL. Blood cancer journal, 14(1), 100. (Read full publication)
    14. Okcu I, Wang Y, Bock AM, Zhou J, Moustafa MA, Tun HW, Rosenthal AC, Johnston PB, Baidoun F, Khurana A, Kabat BF, King RL, Habermann TM, Nowakowski G (2024). Incidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System Prophylaxis. Clinical lymphoma, myeloma & leukemia,
    15. Epperla N, Zayac AS, Landsburg DJ, Bock AM, Nowakowski GS, Ayers EC, Girton MR, Hu M, Beckman AK, Li S, Medeiros LJ, Chang JE, Kurt H, Sandoval-Sus J, Ansari-Lari MA, Kothari SK, Kress A, Xu ML, Torka P, Sundaram S, Smith SD, Naresh KN, Karimi YH, Bond DA, Evens AM, Naik SG, Kamdar M, Haverkos BM, Karmali R, Farooq U, Vose JM, Rubinstein PG, Chaudhry A, Olszewski A (2024). High-Grade B-Cell Lymphoma, Not Otherwise Specified: CNS Involvement and Outcomes in a Multi-Institutional Series. Blood advances, 8(20), 5355-5364. (Read full publication)
    16. Bock AM, Wenzl K, Novak JP, Stokes ME, Hopper MA, Krull JE, Dropik AR, Sarangi V, Ortiz M, Stong N, Huang CC, Maurer MJ, King RL, Farooq U, Wang Y, Witzig TE, Ansell SM, Habermann TM, Cerhan JR, Gandhi AK, Nowakowski G, Novak A (2025). Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment Resistance. Hematological oncology, 43(1), e70006. (Read full publication)
    17. Pierce AL, Okcu I, Nowakowski G, Tolu S, Amengual J, Ross C, Graber J, Bock A, Hu B, Ermann (2025). HSR25-185: A Multicenter Retrospective Study of Treatment and Survival Outcomes of Patients With Secondary CNS Relapsed DLBCL in the Modern Era. Journal of the National Comprehensive Cancer Network, 23(3.5), (Read full publication)
    18. Baron K, Anto E, Esther J, Vardell VA, Pappas L, Bock A, Ermann DA, Fitzgerald LA, Hu B, Shah H (2025). Comparison of Real-World Outcomes in Patients with Follicular Lymphoma treated with BR vs RCHOP-like regimens. Clinical lymphoma, myeloma & leukemia,
    19. Bock AM, Mwangi R, Wang Y, Khurana A, Maurer MJ, Ayers A, Kahl BS, Martin P, Cohen JB, Casulo C, Lossos IS, Farooq U, Ayyappan S, Reicks TW, Habermann TM, Witzig TE, Flowers CR, Cerhan JR, Nastoupil LJ, Nowakowski G (2025). Defining Primary Refractory Large B-cell Lymphoma. Blood advances,
    20. Novak A, Walker J, Wenzl K, Novak J, Stokes M, Hopper M, Dropik A, Siminski M, Bock AM, Sarangi V, Ortiz M, Stong N, Huang C, Maurer M, Link B, Ansell S, Habermann T, Witzig T, King R, Nowakowski G, Cerhan J, and Gandhi Integrated genomics with refined cell-of-originsubtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuselarge B cell lymphoma. Blood cancer journal,
    21. Walker JS, Wenzl K, Novak JP, Stokes ME, Hopper MA, Dropik AR, Siminski MS, Bock AM, Sarangi V, Ortiz M, Stong N, Huang CC, Maurer MJ, Link BK, Ansell SM, Habermann TM, Witzig TE, King RL, Nowakowski G, Cerhan JR, Gandhi AK, Novak A (2025). Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphoma. Blood cancer journal, 15(1), 120. (Read full publication)
    22. Loftus TJ, Cho JY, Meraz M, Dhippayom T, Bock AM, Wagner CB, Thavorn K, Chaiyakunapruk (2025). Cost-effectiveness of chimeric antigen receptor T-cell therapy for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis. Journal of medical economics, 28(1), 2216-2235. (Read full publication)

    Review

    1. Bock AM, Nowakowski GS, Wang (2022). Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. Current treatment options in oncology, 23(2), 155-170. (Read full publication)
    2. Bock AM and Epperla Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies. Journal of hematology & oncology,
    3. Bock AM, Epperla (2025). Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies. Journal of hematology & oncology, 18(1), 68. (Read full publication)

    Letter

    1. Bock AM, Pollyea D (2020). Venetoclax with azacitidine for two younger Jehovah's Witness patients with high risk acute myeloid leukemia. American journal of hematology, (Read full publication)
    2. Ng WL, Wang Y, Bock AM, Jevremovic D, Wang ML, Nowakowski G (2023). Review of management options for mantle cell lymphoma in pregnancy. Leukemia & lymphoma, 64(6), 1194-1198. (Read full publication)

    Abstract

    1. Bock A.M., Baron K., Wagner C., Fitzgerald L., Ermann D., Hu B., Shah H., Zak J., Epperla N (2025). Impact Of the Neutrophil/Lymphocyte Ratio on Outcomes Following Bispecific Antibody Therapy in Relapsed/Refractory Lymphoma Patients.
    2. Jallouk A., Feng L., Ayers A., Chauhan A., Thiruvengadam S., Bock A., Bhaskar S., Epperla N., Herrera A., Ahmed S (2025). Real-World Outcomes of Mosunetuzumab Use from the Cubic Consortium.
    3. Baron K., Wagner C., Fitzgerald L.A., Ermann D.A., Hu B., Epperla N., Shah H.A., Bock A (2025). A Standardized Process for a Rapid Dose Escalation of Epcoritamab for Patients with Lymphoid Malignancies in the United States.
    4. Bock A.M., Feng L., Ayers A., Chauhan A., Thiruvengadam S., Jallouk A., D'Angelo C., Sawalha Y., Godbole S., Merryman R., Bhaskar S., Baron K., Lunning M., Herrera A., Crombie J.L., Epperla N., Ahmed S (2025). Real-World Safety and Efficacy of Epcoritamab for Patients with Relapsed/Refractory Large B-Cell Lymphomas.
    5. Shouse G., Ahmed S., Chen L., Salles G., Bock A.M., Lunning M.A., Godbole S., Sawalha Y., Ayers A.A., Thiruvengadam S., Goth C., Flowers C.R., Chauhan A., Epperla N., Herrera A., Danilov A.V., Falchi L (2025). Glofitamab for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma, a Real-World Evidence Study from the Cubic Consortium.
    6. Steiner R., Bock A.M., Herrera A.F., Zulfa O., Hoffmann M., Ibrahimi S., Galanina N., Lee H.J., Green M., Lin R., Pinnix C.C., Moskowitz A., Yahalom J., Chihara D (2025). CTEP Trial 10590, Norm: Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial With Either Rituximab or Mosunetuzumab.

    Other

    1. Stromich J, Saleh J, Jha P, Bangalore-Raju S, Bock A, Singh M, Lamb G, Tyagi S, Pfeifer K, Katz A, Wagle J, Dang G, Koerner K, Lalehzari M (2017). Cases from the Medical College of Wisconsin. Ocular syphilis, cefepime neurotoxicity, primary empty sella, and more. ACP Hospitalist.